Prognostic impact of co-morbidities on long-term prognosis in patients with reduced and preserved ejection fraction following acute myocardial infarction
Clinical experience and safety of ferric carboxymaltose for treating iron deficiency in heart failure patients with mildly reduced and preserved left ventricular ejection fraction.
Speaker:
Doctor A. Esteban Fernandez (Leganes, ES)
Soluble transferrin receptor as a marker of tissue iron deficiency: impact on health-related quality of life in patients with heart failure without systemic iron deficiency or anaemia
Speaker:
Mr R. Ramos Polo (Hospitalet De Llobregat, ES)
Infection risk with ferric derisomaltose compared to standard of care in patients with heart failure and iron deficiency: a prespecified analysis of the IRONMAN trial